´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancer : 2023-04-21
±³À°ÀÏÀÚ : 2023-04-21
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» È£ÅÚ ÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ
±³À°ÁÖÁ¦ : Recent updates in GU Cancer
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 02-735-2856
À̸ÞÀÏ : meetings@ksmo.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í ±¸ºÐ »çÀüµî·Ï (2023³â 4¿ù 3ÀÏ(¿ù)±îÁö) ÇöÀåµî·Ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ ȸ¿ø 50,000¿ø 70,000¿ø ºñȸ¿ø ±³¼ö/ºÀÁ÷ÀÇ/°³¿øÀÇ/Àü¹®ÀÇ/¹Ú»ç±Þ ¿¬±¸¿ø 60,000¿ø 80,000¿ø ÀüÀÓÀÇ/Àü°øÀÇ/°øº¸ÀÇ/±ºÀÇ°ü/¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¹× Çлý/°£È£»ç 30,000¿ø 50,000¿ø ¾÷ü ¹× ±âŸ 70,000¿ø 90,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 09:20~09:40 Adjuvant Therapy in Renal Cell Carcinoma: New Data of Immunotherapy ±Ç¹Î¼®(¾ÆÁִ뺴¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 09:40~10:00 Advanced clear cell Renal Cell Carcinoma: Beyond the Health Insurance Reimbursement ¹ÚÁÖȯ(°¡Ãµ´ë±æº´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 10:00~10:20 Non-clear cell renal cell carcinoma: How to Best Treat? ÀÓÁÖÇÑ(ÀÎÇϴ뺴¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 10:20~10:40 2022 WHO Classification Updates in RCC º´¸®°ú Á¶¿µ¹Ì(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 04-21 ´ÙÀ̾ƸóµåȦ 10:40~10:50 Discussion ()
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 11:00~11:20 Systemic treatment of Advanced UC: New Data of Combination Therapy or Switch-Maintenance ±èÇöÈ£(¼ººó¼¾Æ®º´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 11:20~11:40 Subsequent treatment after platinum and IO: New Data of Targeted Therapy and ADC ±èÁÂÈÆ(°í·Á´ë ¾È¾Ïº´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 11:40~12:00 Neoadjuvant and adjuvant Therapy in BC ¹Ú±Ç¿À(¾ç»êºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 12:00~12:20 Adjuvant and Neoadjuvant Therapy in UTUC ÀÓÇö¼ö(¿ï»ê´ëÇб³º´¿ø)
Åä·Ð 04-21 ´ÙÀ̾ƸóµåȦ 12:20~12:30 Discussion All()
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 12:30~13:10 Evolving treatment paradigm of mCRPC with Olaparib ±èÀÎÈ£(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 13:40~14:00 Metastatic HSPCa, Do we need risk-adapted approach for systemic therapy ±èÈñÁØ(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 14:00~14:20 Metastatic CRPC: How to best treat patients with HRR defects ±èâ°ï(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 14:20~14:40 Metastatic CRPC: How to best use subsequent therapy after ADT and ARTA failure ±è¾îÁø(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 04-21 ´ÙÀ̾ƸóµåȦ 14:40~15:00 Oligometastatic disease in prostate cancer: Does it really matter? ¹ÚÀαÙ(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 04-21 ´ÙÀ̾ƸóµåȦ 15:00~15:10 Discussion All()